Australia markets closed

Monopar Therapeutics Inc. (MNPR)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.6350-0.0400 (-5.93%)
At close: 04:00PM EDT
0.6400 +0.00 (+0.79%)
After hours: 06:44PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 11.18M
Enterprise value 3.91M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.49
Enterprise value/revenue N/A
Enterprise value/EBITDA -2.42

Trading information

Stock price history

Beta (5Y monthly) 1.18
52-week change 3-13.14%
S&P500 52-week change 321.83%
52-week high 31.7300
52-week low 30.2739
50-day moving average 30.7239
200-day moving average 30.5788

Share statistics

Avg vol (3-month) 3112.53k
Avg vol (10-day) 364.36k
Shares outstanding 517.6M
Implied shares outstanding 618.2M
Float 88.1M
% held by insiders 153.61%
% held by institutions 12.26%
Shares short (28 June 2024) 482.8k
Short ratio (28 June 2024) 40.4
Short % of float (28 June 2024) 41.60%
Short % of shares outstanding (28 June 2024) 40.47%
Shares short (prior month 31 May 2024) 462.57k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-48.38%
Return on equity (ttm)-92.67%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
Net income avi to common (ttm)-7.61M
Diluted EPS (ttm)-0.5200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)8.79M
Total cash per share (mrq)0.5
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)6.21
Book value per share (mrq)0.43

Cash flow statement

Operating cash flow (ttm)-7.24M
Levered free cash flow (ttm)-4.73M